Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasitibant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 known ✓ | P30411 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasitibant SCHEMBL29379526 | 1.00 | BDKRB2 (1.00) | BDKRB2 | |
| Fasitibant SCHEMBL16982331 | 0.99 | BDKRB2 (0.99) | BDKRB2 | |
| Fasitibant SCHEMBL2641709 | 0.99 | BDKRB2 (1.00) | BDKRB2 | |
| Fasitibant SCHEMBL29537993 | 0.99 | BDKRB2 (1.00) | BDKRB2 | |
| Fasitibant SCHEMBL2337275 | 0.99 | BDKRB2 (1.00) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL3550895 | 0.95 | BDKRB2 (0.99) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL3550900 | 0.95 | BDKRB2 (0.99) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL5174610 | 0.94 | BDKRB2 (0.98) | BDKRB2 | |
| SCHEMBL5184822 | 0.94 | BDKRB2 (1.00) | BDKRB2 | |
| SCHEMBL5184814 | 0.94 | BDKRB2 (1.00) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645759-B2 | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-01-12 | — | — | US | claimed |
| EP-1799214-B8 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | LUSO FARMACO INST (IT) | 2008-06-18 | — | — | EP | claimed |
| EP-1799214-B1 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | LUSO FARMACO INST (IT) | 2007-12-26 | — | — | EP | claimed |
| US-20070281944-A1 | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2007-12-06 | — | — | US | claimed |
| EP-1799214-A1 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Instituto Luso Farmaco d'Italia S.P.A. (IT) | 2007-06-27 | — | — | EP | claimed |
| WO-2006040004-A1 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2006-04-20 | — | — | WO | claimed |
| US-7645759-B2 | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-01-12 | — | — | US | disclosed |
| EP-1799214-B8 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | LUSO FARMACO INST (IT) | 2008-06-18 | — | — | EP | disclosed |
| EP-1799214-B1 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | LUSO FARMACO INST (IT) | 2007-12-26 | — | — | EP | disclosed |
| US-20070281944-A1 | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2007-12-06 | — | — | US | disclosed |
| EP-1799214-A1 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Instituto Luso Farmaco d'Italia S.P.A. (IT) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006040004-A1 | NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281944-A1 | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | BDKRB2, BDKRB1, BRS3 | BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.